Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment

The European Commission has approved the use of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The combination is now licensed for use within the European Union. The Medicines and Healthcare products Regulatory Agency (MHRA) will need to approve the nivolumab plus cabozantinib combination before it […]

read more

European Commission approves avelumab plus axitinib combination for the first-line treatment of advanced kidney cancer

Based on the findings from the pivotal phase III JAVELIN Renal 101 study, the European Commission has approved avelumab in combination with axitinib for the first-line treatment of advanced renal cell carcinoma (RCC). JAVELIN Renal 101 demonstrated that avelumab in combination with axitinib significantly lowered risk of disease progression or death by 31% and nearly […]

read more

European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer

Based on the findings from the pivotal phase 3 KEYNOTE-426 trial, the European Commission has today approved pembrolizumab (anti-PD-1 therapy) in combination with axitinib (tyrosine kinase inhibitor) for patients with untreated, advanced renal cell carcinoma (RCC). The KEYNOTE-426 trial demonstrated a reduced risk of death by 47% with the combination compared to sunitinib in patients […]

read more

European Commission approves cabozantinib for first-line kidney cancer

The European Commission has approved cabozantinib (Cabometyx) for the first-line treatment of advanced renal cell carcinoma (RCC).  The approval is based on data from the CABOSUN trial, which demonstrated that cabozantinib significantly prolongs progression-free survival (PFS) compared to sunitinib in people with untreated advanced RCC at intermediate or poor-risk of the cancer spreading. Cabozantinib, a […]

read more
Showing all 4 results
  TOP